ImpediMed study published in peer-reviewed journal

Company News

by Kathy Skantzos

ImpediMed (ASX:IPD), a global provider of medical technology, announced its study has been published in a peer-reviewed medical journal.

The study involves the effectiveness of L-Dex for the screening, intervention and prevention of disease progression.

The 6-year study was conducted at the Nashville Breast Centre, comprising retrospective analysis and examination of nearly 600 breast cancer patients at risk of developing lymphodema.

CEO and Managing Director of ImpediMed Richard Carreon said the published study adds to the peer-reviewed evidence supporting the clinical impact of using L-Dex.

ImpediMed was the first company to receive FDA approval to clinically assess lymphodema for its L-Dex device.

Shares in ImpediMed (ASX:IPD) are trading 6.33 per cent lower to $0.74.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.